

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the “Announcement in Relation to the Progress of Drug Clinical Trial By a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Yuqing

Chairman

Shanghai, the PRC

13 August 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* for identification purposes only

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Progress of Drug Clinical Trial By a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the “**Company**”), initiated the Phase II clinical trial of FXS7553 (formerly project no.: XH-S004) for the treatment of chronic obstructive pulmonary disease in China¹.

II. Basic Information and Research Progress of FXS7553

FXS7553 is a small molecule oral DPP-1 inhibitor independently developed by the Group (i.e., the Company and its subsidiaries/units, the same hereinafter), which is intended to be used for the treatment of non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease and others. As of the date of this announcement (i.e., 13 August 2026, the same hereinafter), another indication of FXS7553 (for the treatment of non-cystic fibrosis bronchiectasis) is at the stage of Phase II clinical trial in China.

As of July 2026, the Group had invested approximately RMB 151 million (unaudited) in total in the research and development (the “R&D”) of FXS7553 at this stage.

¹ excluding Hong Kong, Macau and Taiwan for the purpose of this announcement, the same applies below.

As of the date of this announcement, no drug with the same molecular mechanism has been approved for marketing in China.

III. Risk Reminder

As required by the relevant laws and regulations, the FXS7553 is subject to undergo a series of clinical studies and approval by the relevant national drug review department in China before it can be launched. There are certain risks in the R&D of drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and launch of drugs is a long-term task involving various uncertainties. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

13 August 2026

* For identification purpose only